rethinkTHC Search
Menu
Study breakdown

Prenatal Cannabinoid Exposure Permanently Altered the Endocannabinoid System in Adult Rat Brains

Animal StudyPreliminary evidence
The takeaway

Rats exposed to a synthetic cannabinoid during fetal development showed lasting changes in their brain's endocannabinoid system as adults, even though their movement appeared normal.

Read this if you want to understand how prenatal cannabinoid exposure might permanently change brain chemistry.

CB1 receptor sensitivity shifted -26% in hippocampus, +27% in striatum of prenatally exposed rats

What the researchers found

Pregnant rats received daily doses of WIN 55,212-2 (a potent synthetic cannabinoid) from gestational day 5 through 20. Their adult male offspring showed significant alterations in the endocannabinoid system compared to controls.

In the striatum (a brain region involved in movement and reward), adult offspring had increased anandamide levels, reduced FAAH enzyme activity (which breaks down anandamide), and enhanced NAPE-PLD activity (which produces anandamide). In limbic areas (involved in emotion), the opposite pattern emerged.

CB1 receptor sensitivity was altered in the hippocampus (reduced by 26%) and striatum (increased by 27%), despite receptor numbers remaining unchanged. Notably, the animals' ambulatory activity appeared normal despite these neurochemical changes.

Why it matters

This study demonstrated that prenatal cannabinoid exposure can produce permanent, region-specific changes in the brain's endocannabinoid system that persist into adulthood. These changes occurred in brain areas critical for learning, memory, motor function, and emotional behavior.

The numbers in context

CB1 receptor sensitivity changed: hippocampus -26%, striatum +27%. Striatal anandamide levels increased with reduced FAAH and enhanced NAPE-PLD activity. Limbic areas showed opposite changes.

How the study worked

Pregnant rats were treated daily with WIN 55,212-2 (0.5 mg/kg) or vehicle from gestational day 5 to 20. Adult male offspring underwent radioligand binding assays and GTPgammaS functional assays to measure CB1 receptor density, affinity, and function across multiple brain regions. Anandamide levels and enzyme activities were also quantified.

What this study cannot tell us

WIN 55,212-2 is a synthetic cannabinoid more potent than THC, so findings may not directly translate to cannabis use during pregnancy. Only male offspring were studied. Behavioral testing was limited to ambulatory activity and did not assess cognitive or emotional function.

How to read the evidence

This is an animal study using a synthetic cannabinoid, not THC. While it demonstrates lasting neurochemical changes, translation to human cannabis use during pregnancy requires significant caution.

When this study was published

Published in 2007. Subsequent animal and human studies have continued to explore prenatal cannabinoid exposure effects on neurodevelopment.

The bigger picture

While this study used a synthetic cannabinoid rather than THC, the findings raise questions about whether any cannabinoid exposure during fetal development might permanently alter the developing endocannabinoid system. The region-specific nature of the changes suggests complex, long-lasting neuroadaptations rather than simple global effects.

Questions still open

  • Would THC produce similar long-term endocannabinoid changes? Are these neurochemical alterations associated with cognitive or behavioral differences that weren't measured? Do female offspring show different patterns?

Common questions

Is WIN 55,212-2 the same as THC?
No. WIN 55,212-2 is a synthetic cannabinoid that activates the same receptors as THC but is significantly more potent. Results with this compound may not directly reflect what happens with cannabis use.
If the rats moved normally, why does it matter?
Movement is just one measure. The endocannabinoid system affects learning, memory, emotion, and reward processing. The study didn't test these other functions, so hidden behavioral effects may exist despite normal locomotion.

Read the original research

Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.

European journal of pharmacology, 573(1-3), 11-9

Citation

Castelli, M Paola; Paola Piras, A; D'Agostino, Antonella; Pibiri, Fabio; Perra, Simona; Gessa, Gian Luigi; Maccarrone, Mauro; Pistis, Marco. (2007). Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.. European journal of pharmacology, 573(1-3), 11-9.

Explore the wider topic